Optimisation of second line antihormonal treatment for castration resistant metastatic prostate cancer

Background: The prognosis of castration resistant metastatic prostate cancer has been improved by several recently introduced therapeutic options, among others the second line antihormonal agents. Still, several questions related to the optimal use of these new drugs have remained open. The followin...

Full description

Bibliographic Details

Published in:	Journal of Men's Health
Main Authors:	Kullmann Tamás, Kocsis Károly, Ambrus Adél, Kránitz Noémi, Herczeg Ágnes, Szepesváry Zsolt
Format:	Article
Language:	English
Published:	MRE Press 2022-04-01
Subjects:	prostate cancer abiraterone enzalutamide hydrocortisone biological progression
Online Access:	https://www.imrpress.com/journal/JOMH/18/4/10.31083/j.jomh1804093